In this webinar, discover how amorphous solid dispersions (ASDs) can significantly enhance the bioavailability of poorly soluble drug candidates and accelerate their path to the clinic.
You’ll learn how ASDs improve solubility and performance, with a focus on hot melt extrusion (HME) as a robust, scalable, and cost-effective manufacturing technology. Using griseofulvin as a model compound, Lonza experts will share results from recent lab-scale (5 mm) and pilot-scale (18 mm) extrusion studies, highlighting how key process parameters impact ASD quality.
The session will explore how variables such as melt temperature, residence time, and shear rate influence the physical state and stability of the dispersion, and how these parameters can be effectively controlled during scale-up. You’ll also gain a clear comparison between HME and spray drying, outlining differences in process control, scalability, and resulting material properties.
Finally, the webinar will provide an overview of Lonza’s formulation and manufacturing capabilities for both hot melt extrusion and spray-dried dispersions (SDDs) at the Bend site, illustrating how the right technology choice can de-risk development and support successful commercialization.
Key Learning Objectives:
- Understand the role of ASDs in improving drug bioavailability
- Discover how hot melt extrusion enables scalable ASD manufacturing
- Learn which process variables most influence ASD quality and scale-up success
- Compare hot melt extrusion and spray drying approaches for ASD production
